Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2019-09-24 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 30 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, this is to inform you that SEBI vide ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) informing them about a regulatory order from SEBI (Securities Exchange Board of India) dated September 24, 2019. The order prohibits the company from accessing the securities market and restrains it from buying, selling, or dealing in securities for one year. The letter mentions seeking advice for remedies including filing an appeal. The document is an official regulatory announcement about a compliance and enforcement action, not a financial report, earnings release, or management discussion. It does not contain financial data or detailed report content but is a notification under SEBI regulations. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2019-09-24 English
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice for an Extra Ordinary General Meeting (EGM) of Morepen Laboratories Limited. It includes details about the meeting date, venue, agenda items such as increase in authorized share capital and issue of fully convertible warrants on a preferential basis. The document is addressed to stock exchanges and shareholders, providing procedural information about voting rights and proxy appointments. There are no financial statements, audit opinions, or earnings data presented. The content is focused on informing shareholders about the meeting and the resolutions to be considered, which fits the definition of a Proxy Solicitation & Information Statement (PSI).
2019-09-24 English
Pursuant to Regulation 30 read with Part A of Schedule III of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, please ....
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice for an Extra Ordinary General Meeting (EGM) of Morepen Laboratories Limited. It includes details about the meeting date, venue, agenda items such as increase in authorized share capital and issue of fully convertible warrants, and procedural notes for shareholders. There are no financial statements or detailed financial performance data. The document is a formal meeting notice and not a report or transcript. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2019-09-24 English
This is to inform you that the Board of Directors of the Company, in their meeting held on Thursday, 19th September, 2019 subject to approval of members of the Company, considered and approved ....
Capital/Financing Update Classification · 95% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) regarding the outcome of a Board Meeting held on 19th September 2019. The content details the Board's approval for an increase in authorized share capital and the issuance of convertible warrants on a preferential basis. It includes specifics about the number of shares, pricing, investor names, and regulatory references to SEBI Listing Obligations and Disclosure Requirements (LODR) and ICDR Regulations. The document is an announcement of corporate actions related to capital structure changes, specifically the issuance of new securities and increase in authorized capital. It does not contain financial statements or detailed financial performance data, nor is it a transcript, report, or presentation. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (over 10,000 characters) and detailed disclosure support a high confidence in this classification.
2019-09-19 English
Preferential issue
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the outcome of a Board Meeting held on 19th September 2019. The key content includes approval of an increase in authorized share capital and the issuance of warrants convertible into equity shares on a preferential basis. It includes detailed disclosures as required under SEBI Listing Regulations and SEBI circulars about the preferential allotment of securities, including investor names, number of warrants, pricing, and conversion terms. The document is a formal announcement of corporate actions related to capital structure changes and financing activities, not a full financial report or earnings release. It does not contain financial statements or management discussion but focuses on capital issuance and related regulatory disclosures. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2019-09-19 English
Outcome of Board Meeting
Regulatory Filings
2019-09-19 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.